+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study



The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study



Arthritis and Rheumatism 52(8): 2506-2512



To compare the effectiveness of tumor necrosis factor (TNF)-blocking agents (etanercept and infliximab) in patients with rheumatoid arthritis (RA) and patients with ankylosing spondylitis (AS). Data from an ongoing longitudinal, observational study in Norway were used to assess changes in health-related quality of life (HRQOL) in patients with RA (n = 291) and AS (n = 62). Patients received anti-TNF therapy, and changes in scores on the Short Form 36 (SF-36), SF-6D, modified Health Assessment Questionnaire, and visual analog scales for patients' assessments of pain, fatigue, and global status from baseline to followup examinations at 3 and 6 months were compared. Data were adjusted for age, sex, and baseline values and are presented as crude estimates as well as standardized response means. Both groups had improvements in all measures at 3 and 6 months. At 3 months, the changes were significantly better in the AS group compared with the RA group for all measures except the SF-36 social functioning scores. At 6 months, all changes were numerically greater in the AS group. Differences were significant for the SF-36 role emotional scores and were borderline significant for the SF-36 physical functioning, role physical, and vitality scores and for the SF-6D scores. In this real-life setting, patients with AS experienced improvement in HRQOL that was comparable to, and sometimes greater than, that observed in RA patients. These results support the idea that patients with AS should have the same access to TNF-blocking agents as patients with RA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012639719

Download citation: RISBibTeXText

PMID: 16052584

DOI: 10.1002/art.21209


Related references

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis and Rheumatism 59(2): 234-240, 2008

The comparative survival of TNF-blocking agents in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis during one-year follow-up: Results from a longitudinal, observational study. 2006

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Research and Therapy 13(3): R94, 2011

Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Pharmacoeconomics and Outcomes Research 7(2): 155-169, 2007

Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. Journal of Korean Medical Science 29(9): 1205-1211, 2014

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Seminars in Arthritis and Rheumatism 33(4): 283-288, 2004

Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study. American Health and Drug Benefits 3(4): 266-273, 2010

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Research and Therapy 12(3): R117, 2010

AB0292Effect of anti-tumor necrosis factor-a therapies on weight and body mass index in patients with rheumatoid arthritis and ankylosing spondylitis. Annals of the Rheumatic Diseases 72(Suppl 3): A875.4-A876, 2013

AB1120Comparison of Long-Term Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis: A Single Center Turkish Experience Over a Decade. Annals of the Rheumatic Diseases 74(Suppl 2): 1275.2-1276, 2015

Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. Journal of Rheumatology 38(11): 2355-2361, 2011

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Annals of the Rheumatic Diseases 66(10): 1393-1397, 2007

Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis and Rheumatism 64(7): 2068-2077, 2012

Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis and Rheumatism 54(11): 3399-3407, 2006

AB0474Comparison of drug retention rates between anti-tumor necrosis factor agents in rheumatoid arthritis and ankylosing spondylitis in daily clinical practice:. Annals of the Rheumatic Diseases 71(Suppl 3): 664.14-665, 2013